The fact that lenacapavir will soon be available to patients is a testament to the strength of America's biopharmaceutical ...

Lenacapavir offers twice-yearly HIV prevention with near-complete protection in clinical trials. Clinical trials show ...

Shares of Gilead Sciences, Inc. GILD have gained 27.2% in the past six months against the industry’s decline of 2.2%. The ...

The Food and Drug Administration (FDA) recently approved lenacapavir for HIV prevention in both men and women. Many experts believe this twice a year treatment could be a game changer in the fight ...

A new drug that gives almost complete protection against the virus was to be administered across Africa this year. Now, much ...

Clinical trials have shown that six-monthly injections of lenacapavir are almost 100 percent protective against becoming infected with HIV. But big questions remain over the drug’s affordability.

The Food and Drug Administration has approved the world’s only twice-a-year shot to prevent HIV. In two groundbreaking studies, Gilead Sciences’ shot, a drug named lenacapavir, nearly eliminated new ...

Big Pharma delivers another life-saving medical advance, and another demonstration of the folly of price controls.

The FDA has approved a breakthrough preventative treatment for HIV that could change the course of the AIDS epidemic. But ...

The Food and Drug Administration has approved a drug that reduces the chances of contracting HIV. A University of Utah ...

The FDA approved Gilead's HIV prevention drug lenacapavir, a twice-a-year injectable medication that clinical trials show ...

Yeztugo, approved by the FDA, was highly effective in two randomized trials. It costs $28,218 per year, and people have to be ...